Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review
The COVID-19 pandemic has exacerbated mortality rates among immunocompromised
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
patients, accentuating the need for novel, targeted therapies. Transplant recipients, with their …
Mouse models in COVID-19 research: analyzing the adaptive immune response
S Clever, A Volz - Medical microbiology and immunology, 2023 - Springer
The emergence of SARS-CoV-2, the severe acute respiratory syndrome coronavirus type 2
causing the COVID-19 pandemic, resulted in a major necessity for scientific …
causing the COVID-19 pandemic, resulted in a major necessity for scientific …
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
A Papadopoulou, G Karavalakis, E Papadopoulou… - Nature Medicine, 2023 - nature.com
Despite advances, few therapeutics have shown efficacy in severe coronavirus disease
2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective …
2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective …
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)
A Pérez-Martínez, M Mora-Rillo, C Ferreras… - …, 2021 - thelancet.com
Background Effective treatments are still needed to reduce the severity of symptoms, time of
hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes …
hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes …
Upregulation of CCR4 in activated CD8+ T cells indicates enhanced lung homing in patients with severe acute SARS‐CoV‐2 infection
S Spoerl, AN Kremer, M Aigner… - European journal of …, 2021 - Wiley Online Library
COVID‐19 is a life‐threatening disease leading to bilateral pneumonia and respiratory
failure. The underlying reasons why a smaller percentage of patients present with severe …
failure. The underlying reasons why a smaller percentage of patients present with severe …
SARS-CoV-2-specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking, and large-scale production for adoptive cell therapy
C Ferreras, B Pascual-Miguel… - Frontiers in cell and …, 2021 - frontiersin.org
Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak
significantly delaying the hope for the virus' complete eradication. In the absence of effective …
significantly delaying the hope for the virus' complete eradication. In the absence of effective …
Rapid GMP-compliant expansion of SARS-CoV-2–specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19
COVID-19 disease caused by the SARS-CoV-2 virus is characterized by dysregulation of
effector T cells and accumulation of exhausted T cells. T cell responses to viruses can be …
effector T cells and accumulation of exhausted T cells. T cell responses to viruses can be …
[HTML][HTML] Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients
L Peter, DJ Wendering, S Schlickeiser… - … Therapy-Methods & …, 2022 - cell.com
Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that
compromises their immune response to infections and vaccines. For this reason, SOT …
compromises their immune response to infections and vaccines. For this reason, SOT …
Off-the-shelf partial HLA matching SARS-CoV-2 antigen specific T cell therapy: a new possibility for COVID-19 treatment
N Kim, JM Lee, EJ Oh, DW Jekarl, DG Lee… - Frontiers in …, 2021 - frontiersin.org
Background Immunological characteristics of COVID-19 show pathological
hyperinflammation associated with lymphopenia and dysfunctional T cell responses. These …
hyperinflammation associated with lymphopenia and dysfunctional T cell responses. These …
Rapid manufacturing of highly cytotoxic clinical-grade SARS-CoV-2-specific T cell products covering SARS-CoV-2 and its variants for adoptive T cell therapy
A Bonifacius, S Tischer-Zimmermann… - … in Bioengineering and …, 2022 - frontiersin.org
Objectives: Evaluation of the feasibility of SARS-CoV-2-specific T cell manufacturing for
adoptive T cell transfer in COVID-19 patients at risk to develop severe disease. Methods …
adoptive T cell transfer in COVID-19 patients at risk to develop severe disease. Methods …